Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06375798

Clinical Study of Breast Conserving Surgery Combined With Intraoperative Radiotherapy for Early Breast Cancer

A Single-center, open, prospective study,for analyzing the local recurrence rate, the incidence of incision complications and the aesthetic effect of intraoperative radiotherapy in early breast cancer patients after breast-conserving surgery.

Recruiting

Interested in participating?

Request Info

Key information

Age range

55 year and older

Sex eligibility

Female

Study type

Observational

Primary location

The Fourth Hospital of Hebei Medical University

Shijiazhuang, Hebei, China

Location status: Recruiting

Location contact

qimei wang, attending

CONTACT

[email protected]

18633051639

About this study

This is a single-center, open, prospective study. A total of 620 breast cancer patients meeting the exclusion criteria were included and assigned to the IORT group and the WBI group according to the patients' wishes. The IORT group received intraoperative radiotherapy with a regimen of 50-KF-x 20Gy/1f, and the WBI group received whole milk external irradiation with a regimen of 50Gy/25f. If the postoperative paraffin pathology of patients in the IORT group indicated positive axillary lymph nodes, the radiologist should determine whether to irradiate the whole milk and lymph nodes in the drainage area. If the postoperative pathology of patients in the WBI group indicated the need for chemotherapy, radiotherapy was initiated within 6 weeks after the end of chemotherapy, allowing both endocrine therapy and radiotherapy to be performed simultaneously. The clinical standard treatment regimen (chemotherapy, endocrine therapy, etc.) was developed based on postoperative pathological and immunohistochemical reports.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥55 years old;
  • Cytology or histology confirmed invasive breast cancer or intraductal carcinoma in situ (DCIS) with a clinical stage of Tis-1N0M0;
  • Patients who are willing to preserve milk and intend to undergo breast-conserving surgery;
  • If invasive breast cancer is confirmed, the surgical margin negative ≥2mm should be met. If DCIS is confirmed, the surgical margin should be negative ≥3mm;
  • ER≥ 30% and PR≥ 1%, HER2 negative;
  • Voluntary participation in this study, signed informed consent, good compliance, cooperate with follow-up.

Exclusion criteria

  • Simultaneous diagnosis of bilateral or multifocal breast cancer;
  • Previous ipsilateral breast cancer and/or prior chest wall radiation therapy;
  • There are active connective tissue diseases such as scleroderma and systemic lupus erythematosus in the chest;
  • The investigators did not consider the patient suitable for participation in any other conditions of the study.

Treatment and study plan

Radiotherapy

Procedure

If the postoperative paraffin pathology of patients in the IORT group indicated positive axillary lymph nodes, the radiologist should determine whether to irradiate the whole milk and lymph nodes in the drainage area.If the postoperative pathology of patients in the WBI group indicated the need for chemotherapy, radiotherapy was initiated within 6 weeks after the end of chemotherapy, allowing both endocrine therapy and radiotherapy to be performed simultaneously. Clinical standard treatment plan (chemotherapy, endocrine therapy, etc.) was developed based on postoperative pathological and immunohistochemical reports.

Primary outcomes

  1. LRFS

    Time frame: At least 5 years

    There was no local recurrence survival

Study contacts

Contact information is provided by the study sponsor or research team.

cuizhi GENG, archiater

CONTACT

[email protected]

135 0321 6325 ext. 86

meiqi WANG, attending

CONTACT

[email protected]

186 3305 1639

Sponsors and collaborators

Lead sponsor

Hebei Medical University Fourth Hospital

Other

Registry information

Important dates

Study start
2020
Primary completion
2026
Study completion
2026
First posted
Apr 19, 2024
Registry last updated
Sep 15, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.